Metastatic Cancer, Refractory Pain
Conditions
Brief summary
Pain is a common symptom in patients nearing the end of life. Its prevalence varies between 30 and 75%. Nowadays, morphine is the most used molecule as first line treatment of moderate to severe pain. However, this molecule, considering its side effects, may contribute in part to the discomfort of these patients and may increase the pre-existing agitation or delirium. There is therefore a need to find new agents, other than morphine, for pain control at the end of life, without the limitations that the morphine molecule has. The author reviewed the literature on the role of dexmedetomidine in the treatment of refractory symptoms in palliative care, including pain. It is an agonist of the adrenergic alpha 2 receptor having a sedative, analgesic action and a morphine sparing effect demonstrated postoperatively. This study aims primarily at demonstrating that dexmedetomidine has a beneficial role in the treatment of pain in patients with metastatic cancer.
Interventions
DRUGDexmedetomidine
Patients allocated to this group receive a combination of Morphine and Dexmedetomidine
Sponsors
Hotel Dieu de France Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Any painful patient with metastatic cancer * Whatever type of pain: nociceptive, neuropathic, or mixed * Age \> 18 and \<75 years * Patient under analgesic Tier III treatment: with moderate to severe pain and not relieved by non-opioid conventional treatment * Patient cooperating capable of responding to the pain assessment by providing a number from 0 to 10 at the VAS * Patient providing his explicit consent to participate in the study before inclusion (regardless of his inclusion in C or D Group) * Patients with systolic blood pressure (SBP) ≥ 100 mmHg and a diastolic blood pressure (DBP) ≥ 50 mmHg * Patients with a heart rate ≥ 50/min
Exclusion criteria
* Patient refusal to participate in the study or patient unable to give consent * Age \<18 or \> 75 years * Comatose uncooperative patient unable to respond to the assessment of pain by VAS * Hypotensive patients with SBP \< 100 mmHg and DBP \< 60 mmHg or bradycardic with a heart rate \< 50/min * Patient with a heart rhythm disorder, or a disorder of the atrial-ventricular conduction * Patients under beta-blocker * Patient with heart failure with an ejection fraction \< 40% * Patient suffering from allergy or previous intolerance to morphine or dexmedetomidine * Patient with renal impairment with a creatinine clearance \<3 0ml/min/1.73m2, or patient under hemodialysis or peritoneal dialysis. * Patient with severe hepatic impairment with Child-Pugh score at C.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain score | 48 hours | The visual analogue score is used to asses for pain score, the scale varies between 0 and 10 where 0 is no pain and 10 is worst pain encountered |
| Morphine consumption | 48 hours | — |
Outcome results
None listed